Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: J&J/Merck's Mylanta AR

This article was originally published in The Tan Sheet

Executive Summary

J&J/Merck's Mylanta AR: Will enter the H2 antagonist market in January, Merck Senior VP and Chief Financial Officer Judy Lewent said at a Dec. 18 securities analysts meeting in Whitehouse Station, N.J. The product will contain 10 mg famotidine, the active ingredient in J&J/Merck's Pepcid AC. According to the company, in-house research shows that 50% of consumers who suffer from heartburn have not tried an acid blocking product, preferring to stick to more familiar remedies. J&J/Merck hopes the well-known Mylanta name will help lure these cautious consumers into the new category...
Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS086481

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel